A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Deficiencia de glucosilceramidasa; Deficiencia de glucocerebrosidasa
Hay disponibilidad de la terapia de reemplazo enzimático. En los casos graves, se puede necesitar un trasplante de médula ósea.
Para mayor información, se puede contactar a:
La recuperación de una persona depende del subtipo de la enfermedad. La forma infantil de esta enfermedad puede conducir a la muerte temprana y la mayoría de los niños afectados muere antes de los 5 años de edad.
Los adultos con el tipo 1 de la enfermedad pueden esperar una expectativa de vida normal con la terapia de reemplazo enzimático.
Stanley CA, Bennett MJ. Defects of metabolism in lipids. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, eds. Nelson Textbook of Pediatrics. 18th ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 86.
Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic Basis of Disease. 7th ed. St. Louis, Mo: WB Saunders; 2005:163-165.
Sidransky E, Lamarca ME, Ginns EI. Therapy for Gaucher disease: Don't stop thinking about tomorrow. Mol Genet Metab. 2007 Feb;90(2):122-5. Epub 2006 Nov 3.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885